Company intelligence / Profile preview

NAT Diagnostics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

NAT Diagnostics was a molecular diagnostics company founded in 2014, specializing in a Point-of-Care platform for rapid infectious disease testing. Their technology delivered highly accurate results for infectious diseases in 10 minutes using isothermal amplification. The company was acquired by Becton Dickinson on May 15, 2020.

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnostics
Industry: Molecular Diagnostics

Partnerships

JLabs

Beyond the preview

Go deeper on NAT Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAT Diagnostics.

Explore the full profile